Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: A meta-analysis Full Text
BMC Psychiatry,  Clinical Article

Hanwella R et al. – In general atomoxetine and methylphenidate have comparable efficacy and equal acceptability in treatment of ADHD in children and adolescents. OROS methylphenidate is more effective than atomoxetine and may be considered as first line treatment in treatment of ADHD in children and adolescents.

Methods

  • All published, randomized, open label or double blind trials, comparing efficacy of methylphenidate with atomoxetine, in treatment of ADHD in children, diagnosed using DSM-IVTM criteria were included
  • Outcome studied was ADHDRS-IVParent:Inv score
  • Standardized mean difference (SMD) was used as measure of effect size

Results
  • 9 randomized trials comparing methylphenidate and atomoxetine, with a total of 2762 participants were included
  • Meta-analysis did not find significant difference in efficacy between methylphenidate and atomoxetine (SMD= 0.09, 95% CI -0.08-0.26) (Z=1.06, p=0.29)
  • Synthesis of data from eight trials found no significant difference in response rates (RR=0.93 95% CI 0.76-1.14, p=0.49)
  • Sub group analysis showed a significant standardized mean difference favouring OROS methylphenidate (SMD=0.32, 95% CI 0.12-0.53 (Z=3.05, p<0.002)
  • Immediate release methylphenidate was not superior to atomoxetine (SMD= -0.04, 95% CI -0.19-0.12) (Z=0.46, p=0.64)
  • Excluding open label trials did not significantly alter the effect size (SMD=0.08, 95% CI -0.04-0.21) (Z=1.27, p=0.20)
  • All-cause discontinuation was used as a measure of acceptability
  • No significant difference in all cause discontinuation between atomoxetine and methylphenidate (RR 1.22, 95% CI 0.87-1.71)
  • There was significant heterogeneity among the studies (p=0.002, I2=67%)
  • Subgroup analysis demonstrated heterogeneity to be due to open label trials (p=0.001, I2=81%)

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Psychiatry

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Psychiatry Articles

1 Zolpidem and the risk of Parkinson's disease: A nationwide population-based study Journal of Psychiatric Research, August 1, 2014    Clinical Article

2 Antidepressants and the risk of hyponatraemia: A class-by-class review of the literature Psychosomatics, September 15, 2014    Review Article

3 Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis Schizophrenia Research, September 24, 2014    Clinical Article

4 Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis European Neuropsychopharmacology, September 2, 2014    Evidence Based Medicine    Review Article

5 Prazosin in the treatment of PTSD Journal of Psychiatric Practice, July 25, 2014    Review Article

6 Association between early temperament and depression at 18 years Depression and Anxiety, August 18, 2014    Clinical Article

7 The effect of bupropion XL and escitalopram on memory and functional outcomes in adults with major depressive disorder: Results from a randomized controlled trial Psychiatry Research, August 5, 2014    Clinical Article

8 Adipokines as emerging depression biomarkers: A systematic review and meta-analysis Journal of Psychiatric Research, September 18, 2014    Evidence Based Medicine    Clinical Article

9 Latent inhibition in ADHD adults on and off medication: A preliminary study Journal of Attention Disorders, September 10, 2014    Clinical Article

10 Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study Journal of Affective Disorders, July 17, 2014    Clinical Article

11 Adipokines as emerging depression biomarkers: A systematic review and meta-analysis Journal of Psychiatric Research, September 3, 2014    Evidence Based Medicine    Clinical Article

12 Third-wave cognitive therapy versus mentalisation-based treatment for major depressive disorder: a randomised clinical trial BMJ Open, September 9, 2014    Clinical Article

13 The importance of cytokines and autoantibodies in depression Autoimmunity Reviews, September 25, 2014    Review Article

14 Risk of diabetes in children and adolescents exposed to antipsychotics: A nationwide 12-year case-control study Journal of the American Academy of Child & Adolescent Psychiatry, September 4, 2014    Clinical Article

15 Increased cortisol awakening response was associated with time to recurrence of major depressive disorder Psychoneuroendocrinology, August 22, 2014    Clinical Article

16 Association between autoimmune thyroiditis and depressive disorder in psychiatric outpatients European Archives of Psychiatry and Clinical Neuroscience, September 17, 2014    Clinical Article

17 Oral contraceptive use and psychiatric disorders in a nationally representative sample of women Archives of Women's Mental Health, August 29, 2014    Clinical Article

18 Vascular Endothelial Growth Factor: A potential diagnostic biomarker for major depression Journal of Psychiatric Research, September 19, 2014    Clinical Article

19 Efficacy of acupuncture in reducing preoperative anxiety: a meta-analysis Full Text Evidence-based Complementary and Alternative Medicine , September 5, 2014    Free full text    Evidence Based Medicine    Review Article

20 Metacognitions and thought control strategies in unipolar major depression: A comparison of currently depressed, previously depressed, and never-depressed individuals Cognitive Therapy and Research, September 5, 2014    Clinical Article

Indexed Journals in Psychiatry : Current Psychiatry, Bipolar Disorders, American Journal of Psychiatry, Addictionmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close